PMID- 22817667
OWN - NLM
STAT- MEDLINE
DCOM- 20130712
LR  - 20221207
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 12
DP  - 2012 Jul 20
TI  - Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of 
      non small cell lung cancer (NSCLC) in fit elderly patients participating in a 
      prospective phase 2 study (GFPC 0504).
PG  - 301
LID - 10.1186/1471-2407-12-301 [doi]
AB  - BACKGROUND: The median age of newly diagnosed patients with non-small cell lung 
      cancer (NSCLC) is 67 years, and one-third of patients are older than 75 years. 
      Elderly patients are more vulnerable to the adverse effects of chemotherapy, and 
      targeted therapy might thus be a relevant alternative. The objective of this 
      study was to assess the cost-effectiveness of erlotinib followed by chemotherapy 
      after progression, compared to the reverse strategy, in fit elderly patients with 
      advanced NSCLC participating in a prospective randomized phase 2 trial 
      (GFPC0504). METHODS: Outcomes (PFS and overall survival) and costs (limited to 
      direct medical costs, from the third-party payer perspective) were prospectively 
      collected until second progression. Costs after progression and health utilities 
      (based on disease states and grade 3-4 toxicities) were derived from the 
      literature. RESULTS: Median overall survival, QALY and total costs for the 
      erlotinib-first strategy were respectively 7.1 months, 0.51 and 27 734 euro, 
      compared to 9.4 months, 0.52 and 31 688 euro for the chemotherapy-first strategy. 
      The Monte Carlo simulation demonstrates that the two strategies do not differ 
      statistically. CONCLUSION: In terms of cost effectiveness, in fit elderly 
      patients with NSCLC, erlotinib followed by chemotherapy compares well with the 
      reverse strategy.
FAU - Chouaid, Christos
AU  - Chouaid C
AD  - AP-HP Hopital St-Antoine, AP-HP, UMPC, Paris, France. 
      Christos.chouaid@sat.aphp.fr
FAU - Le Caer, Herve
AU  - Le Caer H
FAU - Locher, Chrystelle
AU  - Locher C
FAU - Dujon, Cecile
AU  - Dujon C
FAU - Thomas, Pascal
AU  - Thomas P
FAU - Auliac, Jean Bernard
AU  - Auliac JB
FAU - Monnet, Isabelle
AU  - Monnet I
FAU - Vergnenegre, Alain
AU  - Vergnenegre A
CN  - GFPC 0504 Team
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120720
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - 0 (Taxoids)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 15H5577CQD (Docetaxel)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/economics/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/economics/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*economics
MH  - Cost-Benefit Analysis
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Disease Progression
MH  - Docetaxel
MH  - Erlotinib Hydrochloride
MH  - France
MH  - Health Care Costs
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/*economics
MH  - Monte Carlo Method
MH  - Multivariate Analysis
MH  - Prospective Studies
MH  - Quinazolines/economics/*therapeutic use
MH  - Taxoids/administration & dosage
MH  - Gemcitabine
PMC - PMC3492214
FIR - Vergnenegre, A
IR  - Vergnenegre A
FIR - Melloni, B
IR  - Melloni B
FIR - Barlesi, F
IR  - Barlesi F
FIR - Greillier, L
IR  - Greillier L
FIR - LeCaer, H
IR  - LeCaer H
FIR - Barriere, J R
IR  - Barriere JR
FIR - Geriniere, L
IR  - Geriniere L
FIR - Bombaron, P
IR  - Bombaron P
FIR - Crequit, J
IR  - Crequit J
FIR - Auliac, J B
IR  - Auliac JB
FIR - Le Treut, J
IR  - Le Treut J
FIR - Berard, H
IR  - Berard H
FIR - Thomas, P
IR  - Thomas P
FIR - Muller, P
IR  - Muller P
FIR - Fournel, P
IR  - Fournel P
FIR - Robinet, G
IR  - Robinet G
FIR - Andre, M
IR  - Andre M
FIR - Grivaux, M
IR  - Grivaux M
FIR - Locher, C
IR  - Locher C
FIR - Berdah, J F
IR  - Berdah JF
FIR - Chouaid, C
IR  - Chouaid C
FIR - Baud, M
IR  - Baud M
FIR - Bota, S
IR  - Bota S
FIR - Paillotin, D
IR  - Paillotin D
FIR - Corre, R
IR  - Corre R
FIR - Lena, H
IR  - Lena H
FIR - Chouabe, S
IR  - Chouabe S
FIR - Delhoume, J Y
IR  - Delhoume JY
FIR - Dujon, C
IR  - Dujon C
FIR - Jullian, H
IR  - Jullian H
FIR - Simonian, H
IR  - Simonian H
FIR - David, P
IR  - David P
FIR - Falchero, L
IR  - Falchero L
FIR - Janicot, H
IR  - Janicot H
FIR - Monnet, I
IR  - Monnet I
EDAT- 2012/07/24 06:00
MHDA- 2013/07/16 06:00
PMCR- 2012/07/20
CRDT- 2012/07/24 06:00
PHST- 2012/02/12 00:00 [received]
PHST- 2012/06/27 00:00 [accepted]
PHST- 2012/07/24 06:00 [entrez]
PHST- 2012/07/24 06:00 [pubmed]
PHST- 2013/07/16 06:00 [medline]
PHST- 2012/07/20 00:00 [pmc-release]
AID - 1471-2407-12-301 [pii]
AID - 10.1186/1471-2407-12-301 [doi]
PST - epublish
SO  - BMC Cancer. 2012 Jul 20;12:301. doi: 10.1186/1471-2407-12-301.